A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participants

Prior treatment

• Use of tobacco and nicotine products, defined as any of the below: 1. Smoking more than 5 cigarettes or the equivalent per day 2. Not willing to refrain from smoking and use of nicotine substitute products within 48 hours prior to and during the inpatient periods.
• History (as declared by the participant or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.

Other illness

• Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the participant or reported in the medical records)

Lab values

• HbA1c ≥ 6.5 % (48 mmol/mol) at screening.

• Body mass index (BMI) between 18.5 and 29.9 kg/m2 (both inclusive).
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.